Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)

NCT02478398 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1025

Enrollment

INDUSTRY

Sponsor class

Conditions

Rhinitis, Allergic, Seasonal

Interventions

BIOLOGICAL: Short ragweed pollen allergen extract
BIOLOGICAL: Placebo
DRUG: Self-injectable epinephrine
DRUG: Albuterol/Salbutamol
DRUG: Loratadine
DRUG: Olopatadine
DRUG: Mometasone furoate monohydrate

Sponsor

Merck Sharp & Dohme LLC